# Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis

> **NCT05866926** · PHASE3 · TERMINATED · sponsor: **Ferrer Internacional S.A.** · enrollment: 201 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** FAB122

## Key facts

- **NCT ID:** NCT05866926
- **Lead sponsor:** Ferrer Internacional S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-06
- **Primary completion:** 2024-01-09
- **Final completion:** 2024-02-22
- **Target enrollment:** 201 (ACTUAL)
- **Why stopped:** After the analysis of the main ADORE study it is concluded that there is no clinical benefit for the patients.
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05866926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05866926, "Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05866926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*